



# Real-life Experience with Ceftolozane-Tazobactam in Canada: Results of the CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) Registry

G.G. Zhanel<sup>1</sup>, R. Dhani<sup>2</sup>, M.R. Baxter<sup>1</sup>, J. Kosar<sup>3</sup>, C. Cervera<sup>4</sup>, N. Irfan<sup>5</sup>, R. Zvonar<sup>6</sup>, S. Borgia<sup>7</sup>, J.F. Tessier<sup>8</sup>, G. Dow<sup>9</sup>, R. Ariano<sup>1</sup>, M. Dube<sup>10</sup>, M. Savoie<sup>8</sup>, S. Lutes<sup>11</sup>, A. Walkty<sup>1</sup>, J.A. Karlowsky<sup>1</sup>

University of Manitoba<sup>1</sup>, Winnipeg, MB; London Health Sciences Centre<sup>2</sup>, London, ON; Royal University Hospital<sup>3</sup>, Saskatoon, SK; University of Alberta Hospital<sup>4</sup>, Edmonton, AB; Hamilton Health Sciences Centre<sup>5</sup>, Hamilton, ON; The Ottawa Hospital<sup>6</sup>, Ottawa, ON; Brampton Civic Hospital<sup>7</sup>, Brampton, ON; CIUSSS de l'Est-de-l'Île-de-Montreal<sup>8</sup>, Montreal, QC; The Moncton Hospital<sup>9</sup>, Moncton, ON; Sainte-Croix Hospital<sup>10</sup>, Drummondville, QC; Queen Elizabeth Hospital<sup>11</sup>, Charlottetown, PEI.



Dr. George G. Zhanel  
Department of Medical Microbiology  
Max Rady College of Medicine  
MS673-820 Sherbrook Street  
Winnipeg, MB R3A 1R9  
Email: ggzhanel@pcsineternet.ca

## Introduction


Over the past several years in Canada, when new IV antimicrobials are approved and introduced onto the market, they are used primarily by infectious diseases/medical microbiology specialists and frequently used to treat “off-label” infectious indications. There is commonly limited data sharing between clinicians regarding why they chose to use these new IV antimicrobials (i.e., because of failure, resistance, or adverse effects associated with use of other antimicrobial agents), the types of infections treated, and how (i.e., dosage regimen, duration of therapy, as monotherapy or in combination with one or more other antimicrobial agents) they use new IV antimicrobial agents in real world scenarios. The CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) registry is an initiative coordinated by the Canadian Antimicrobial Resistance Alliance (CARA). CLEAR is a new, national usage registry platform that enables the accumulation of knowledge regarding the clinical usage of new IV antimicrobials recently introduced into the Canadian marketplace. In this study, CLEAR is accumulating data on the usage of ceftolozane/tazobactam across Canada ([https://is.gd/CLEAR\\_ceftolozanetazobactam](https://is.gd/CLEAR_ceftolozanetazobactam)). CLEAR also has IV ceftobiprole and IV fosfomycin in the registry. Links to access these surveys: [https://is.gd/CLEAR\\_ceftobiprole](https://is.gd/CLEAR_ceftobiprole) [https://is.gd/CLEAR\\_IVfosfomycin](https://is.gd/CLEAR_IVfosfomycin)

## Materials and Methods

An IV ceftolozane/tazobactam usage questionnaire was developed using the input of infectious disease/medical microbiology specialists (physicians and pharmacists) across Canada. The CLEAR registry protocol/questionnaire was submitted to and received approval by the Human Ethics Committee at the University of Manitoba (Winnipeg, Canada; April 2019). Using the web-based research data management program, REDCap™ (Research Electronic Data Capture), clinicians (physicians and clinical pharmacists) responded directly to the usage questionnaire online starting June 2019. The REDCap™ online survey link ([https://is.gd/CLEAR\\_ceftolozanetazobactam](https://is.gd/CLEAR_ceftolozanetazobactam)) was distributed via email to >270 CLEAR participants (members of the Association of Medical Microbiology and Infectious Diseases Canada [AMMI] and Canadian Society of Hospital Pharmacists [CSHP]). Clinicians were sent an email every 2 months encouraging their participation in CLEAR. A series of drop-down menus and short answer questions allowed for rapid (~3 minutes) completion of the survey. Clinicians were encouraged to voluntarily complete usage questionnaires for as many patients as possible. The CLEAR ceftolozane/tazobactam questionnaires received by March 15, 2021 were tabulated and results presented are based on 54 patient treatment surveys.

## Results

Below are the cumulative tabulated results of the questions asked in the CLEAR ceftolozane/tazobactam usage survey questionnaires as of March 15, 2021. The following tables are based on a total of 54 patient treatment surveys.



## Acknowledgements

The authors thank all the infectious diseases and medical microbiology experts (physicians and pharmacists) across Canada for submitting patient data and for their support of CLEAR.

Merck Canada provided an unrestricted education grant.

## Survey Access

CLEAR – ceftolozane/tazobactam link  
[https://is.gd/CLEAR\\_ceftolozanetazobactam](https://is.gd/CLEAR_ceftolozanetazobactam)